Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00

Taysha Gene Therapies (NASDAQ:TSHA) had its target price lifted by Robert W. Baird from $7.00 to $12.00 in a research note published on Thursday, Marketbeat reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other research firms also recently commented on TSHA. Chardan Capital raised their target price on Taysha Gene Therapies from $9.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 12th. Needham & Company LLC increased their price target on shares of Taysha Gene Therapies from $8.00 to $10.00 and gave the company a “buy” rating in a report on Thursday. Wells Fargo & Company raised their price objective on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. Finally, Bank of America initiated coverage on shares of Taysha Gene Therapies in a research report on Friday, July 11th. They set a “buy” rating and a $8.00 target price on the stock. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Taysha Gene Therapies currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA opened at $4.76 on Thursday. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -14.00 and a beta of 0.99. The business’s 50 day moving average is $3.03 and its two-hundred day moving average is $2.48. Taysha Gene Therapies has a 12-month low of $1.05 and a 12-month high of $5.40. The company has a current ratio of 12.48, a quick ratio of 12.48 and a debt-to-equity ratio of 0.17.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. The business had revenue of $1.99 million during the quarter, compared to analyst estimates of $1.61 million. Research analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total transaction of $646,000.00. Following the completion of the sale, the insider directly owned 1,006,439 shares of the company’s stock, valued at $3,250,797.97. The trade was a 16.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.78% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. grew its position in Taysha Gene Therapies by 4,105.3% during the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after acquiring an additional 10,068,479 shares during the period. Adage Capital Partners GP L.L.C. acquired a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at about $11,178,000. MPM Bioimpact LLC purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth about $6,823,000. Octagon Capital Advisors LP increased its position in Taysha Gene Therapies by 17.7% during the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after purchasing an additional 1,892,500 shares in the last quarter. Finally, Stempoint Capital LP purchased a new position in Taysha Gene Therapies in the second quarter valued at approximately $2,781,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.